AUROPHARMA is trading at a P/E multiple (18.75x) below weighted average of its peers (354.15x) AUROPHARMA is trading at a P/E multiple (18.75x) below weighted average of its peers (354.15x ...

Shares of Aurobindo Pharma tumbled 9.5 percent to Rs 1,053 on February 19 after the US FDA completed a pre-approval inspection of its subsidiary, Eugia Steriles, issuing five procedural observations.